이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

C4 Therapeutics 배당금

배당금 기준 확인 0/6

C4 Therapeutics 배당금을 지급한 기록이 없습니다.

주요 정보

n/a

배당 수익률

n/a

지급 비율

업계 평균 수익률	2.8%
다음 배당금 지급일	n/a
전 배당일	n/a
주당 배당금	n/a
주당 순이익	-US$1.83
3년 후 배당 수익률 예측	0%

최근 배당금 업데이트

업데이트 없음

Recent updates

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

May 12

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Mar 01

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Feb 29

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Feb 24

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Nov 03

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

May 14

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Sep 29

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

Aug 04

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

May 10

C4 Therapeutics nears three-month high on pre-clinical data for lung cancer therapy

Jun 07

Industry Analysts Just Upgraded Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Revenue Forecasts By 62%

Jun 02

결제의 안정성과 성장

배당금 데이터 가져오기

안정적인 배당: 과거에 CCCC 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.

배당금 증가: CCCC 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.

시장 대비 배당 수익률

C4 Therapeutics 시장 대비 배당 수익률

CCCC 배당 수익률은 시장과 어떻게 비교되나요?
세그먼트	배당 수익률
회사 (CCCC)	n/a
시장 하위 25% (US)	1.5%
시장 상위 25% (US)	4.7%
업계 평균 (Biotechs)	2.8%
3년 후 애널리스트 예측 (CCCC)	0%

주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CCCC 의 배당 수익률을 평가할 수 없습니다.

고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CCCC 의 배당 수익률을 평가할 수 없습니다.

주주에 대한 수익 배당금

수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CCCC 의 지급 비율을 계산하기에는 데이터가 부족합니다.

주주에 대한 현금 배당금

현금 흐름 범위: CCCC 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

C4 Therapeutics 배당금

배당금 기준 확인 0/6

주요 정보

최근 배당금 업데이트

Recent updates

C4 Therapeutics, Inc. Announces Board and Committee Changes

Consensus EPS estimates upgraded to US$1.59 loss, revenue downgraded

Analysts Just Published A Bright New Outlook For C4 Therapeutics, Inc.'s (NASDAQ:CCCC)

Price target decreased by 30% to US$11.88

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

C4 Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

C4 Therapeutics' TORPEDO Platform Is Promising, But Its Valuation Remains Stretched

Consensus revenue estimates increase by 12%

Party Time: Brokers Just Made Major Increases To Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Earnings Forecasts

Price target increased by 8.0% to US$16.00

C4 Therapeutics, Inc. (NASDAQ:CCCC) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2023 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Price target decreased by 13% to US$15.50

C4 Therapeutics, Inc. announced that it has received $24.999997 million in funding from Betta Pharmaceuticals Co., Ltd.

C4 Therapeutics, Inc. Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

New major risk - Share price stability

C4 Therapeutics, Inc. Appoints Owen Hughes to Its Board of Directors

Price target decreased by 13% to US$16.20

Price target decreased by 12% to US$16.40

New Forecasts: Here's What Analysts Think The Future Holds For C4 Therapeutics, Inc. (NASDAQ:CCCC)

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Price target decreased by 31% to US$13.11

C4 Therapeutics, Inc. Announces Upcoming Data Presentations for CFT8634 and CFT7455

Price target increased by 7.4% to US$20.40

Consensus revenue estimates decrease by 27%, EPS upgraded

Price target decreased by 9.3% to US$17.23

C4 Therapeutics, Inc. Appoints Mary Christian as Senior Vice President, Regulatory

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

C4 Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for CFT8919

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell Small Cap Comp Value Index

C4 Therapeutics, Inc. Appoints Leonard (Len) Reyno as Chief Medical Officer, Effective July 10, 2023

C4 Therapeutics, Inc. announced that it expects to receive $25 million in funding from Betta Pharmaceuticals Co., Ltd.

Price target decreased by 8.1% to US$19.23

Analysts Are Betting On C4 Therapeutics, Inc. (NASDAQ:CCCC) With A Big Upgrade This Week

Consensus revenue estimates decrease by 16%, EPS upgraded

Price target decreased by 30% to US$14.83

Price target increased by 10% to US$23.73

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus revenue estimates decrease by 17%

Full year 2022 earnings: EPS and revenues miss analyst expectations

C4 Therapeutics, Inc. Announces Executive Changes

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC(Tm) Degrader, in BRAF V600 Mutant Solid Tumors

Price target decreased to US$23.46

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

C4 Therapeutics wins FDA nod to study cancer candidate in solid tumors

Consensus revenue estimates increase by 16%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

C4 Therapeutics GAAP EPS of -$0.56 beats by $0.12, revenue of $13.84M beats by $5.33M

C4 Therapeutics, Inc. Appoints Laura Bessen and Donna Grogan to its Board of Directors

C4 Therapeutics, Inc.(NasdaqGS:CCCC) dropped from Russell 2000 Growth Index

C4 Therapeutics, Inc. Announces Alain J. Cohen Withdrawal as a Director Nominee for Re-Election At the 2022 Annual Meeting

C4 Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-Null Tumors

Consensus EPS estimates fall by 11%

Price target decreased to US$29.00

Earnings Release: Here's Why Analysts Cut Their C4 Therapeutics, Inc. (NASDAQ:CCCC) Price Target To US$29.00

First quarter 2022 earnings: EPS and revenues miss analyst expectations

C4 Therapeutics: Poor Data Destroyed Preclinical Promise

C4 Therapeutics, Inc., Annual General Meeting, Jun 22, 2022

Price target decreased to US$34.73

Chief Scientific Officer exercised options to buy US$263k worth of stock.

CEO, President & Director recently bought US$84k worth of stock

Price target decreased to US$40.55

Price target decreased to US$40.55

C4 Therapeutics, Inc. Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$54.40

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

Chief Medical Officer exercised options and sold US$378k worth of stock

Chief Scientific Officer exercised options to buy US$707k worth of stock.